[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …

…, G Poulakou, H Milionis, S Metallidis, G Adamis… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

…, P Mavroudis, C Sidiropoulou, G Adamis… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

[HTML][HTML] ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk

…, M Kostoula, M Paneta, G Adamis… - Frontiers in …, 2022 - frontiersin.org
In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG)
vaccination reduced the occurrence of new infections compared to placebo vaccination in the …

Determinants of intention to get vaccinated against COVID-19 among healthcare personnel in hospitals in Greece

…, I Drositis, E Bolikas, C Ledda, G Adamis… - Infection, Disease & …, 2021 - Elsevier
Background To investigate intention rates to get vaccinated against COVID-19 among
healthcare personnel (HCP) in Greece. Methods Cross-sectional survey. Results The response …

[HTML][HTML] Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece

…, V Papastamopoulos, V Paparizos, G Adamis… - PLoS …, 2020 - journals.plos.org
Background Although combined antiretroviral therapy has substantially improved the
prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general …

[HTML][HTML] Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the …

…, IM Gounaridi, E Christaki, S Metallidis, G Adamis… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …

Estimation of the determinants for HIV late presentation using the traditional definition and molecular clock‐inferred dates: Evidence that older age, heterosexual risk …

EG Kostaki, S Limnaios, G Adamis, G Xylomenos… - HIV …, 2022 - Wiley Online Library
Objectives HIV late presentation (LP) has been increasing in recent years in Europe. Our
aim was to investigate the characteristics of LP in Greece using in addition to the traditional …

[HTML][HTML] Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug

…, V Papastamopoulos, A Antoniadou, G Adamis… - Viruses, 2022 - mdpi.com
Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand
transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we …

Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment

…, G Koratzanis, M Kanellopoulou, G Adamis… - International journal of …, 2010 - Elsevier
The objectives of this study were to explore the epidemiological features and resistance rates
in uropathogens isolated from cases of acute uncomplicated cystitis (AUC) in Greece, and …

Vaccination coverage rates and attitudes towards mandatory vaccinations among healthcare personnel in tertiary-care hospitals in Greece

…, M Ploumidis, A Spyrou, M Chini, G Adamis… - Expert Review of …, 2022 - Taylor & Francis
Objectives Our aim was to estimate vaccination and susceptibility rates against vaccine-preventable
diseases among healthcare personnel (HCP) in eight hospitals. Methods Cross-…